Dr Reddy’s Launches India’s First Generic Semaglutide Injection ‘Obeda’ for Type 2 diabetes treatment
Hyderabad, Mar 21 (TNT): Dr. Reddy’s Laboratories on Saturday announced the launch of its injectable semaglutide, branded as Obeda®, marking India’s first generic version approved by the Drugs Controller General of India (DCGI) for the treatment of Type 2 diabetes. In a release, the Hyderabad […….]
